vs
Alkermes plc.（ALKS）与拜玛林制药（BMRN）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Alkermes plc.的2.3倍（$874.6M vs $384.5M），Alkermes plc.净利率更高（12.8% vs -5.3%，领先18.2%），拜玛林制药同比增速更快（17.0% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $58.9M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
ALKS vs BMRN — 直观对比
营收规模更大
BMRN
是对方的2.3倍
$384.5M
营收增速更快
BMRN
高出27.6%
-10.6%
净利率更高
ALKS
高出18.2%
-5.3%
自由现金流更多
ALKS
多$111.1M
$58.9M
两年增速更快
BMRN
近两年复合增速
4.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $874.6M |
| 净利润 | $49.3M | $-46.6M |
| 毛利率 | 88.0% | 68.5% |
| 营业利润率 | 15.1% | -5.1% |
| 净利率 | 12.8% | -5.3% |
| 营收同比 | -10.6% | 17.0% |
| 净利润同比 | -66.3% | -137.3% |
| 每股收益（稀释后） | $0.29 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSBMRN
| Q4 25 | $384.5M | $874.6M | ||
| Q3 25 | $394.2M | $776.1M | ||
| Q2 25 | $390.7M | $825.4M | ||
| Q1 25 | $306.5M | $745.1M | ||
| Q4 24 | $430.0M | $747.3M | ||
| Q3 24 | $378.1M | $745.7M | ||
| Q2 24 | $399.1M | $712.0M | ||
| Q1 24 | $350.4M | $648.8M |
净利润ALKSBMRN
| Q4 25 | $49.3M | $-46.6M | ||
| Q3 25 | $82.8M | $-30.7M | ||
| Q2 25 | $87.1M | $240.5M | ||
| Q1 25 | $22.5M | $185.7M | ||
| Q4 24 | $146.5M | $124.9M | ||
| Q3 24 | $92.4M | $106.1M | ||
| Q2 24 | $91.4M | $107.2M | ||
| Q1 24 | $36.8M | $88.7M |
毛利率ALKSBMRN
| Q4 25 | 88.0% | 68.5% | ||
| Q3 25 | 86.9% | 82.0% | ||
| Q2 25 | 87.3% | 81.8% | ||
| Q1 25 | 83.9% | 79.7% | ||
| Q4 24 | 85.6% | 81.8% | ||
| Q3 24 | 83.3% | 74.7% | ||
| Q2 24 | 84.6% | 81.7% | ||
| Q1 24 | 83.3% | 80.7% |
营业利润率ALKSBMRN
| Q4 25 | 15.1% | -5.1% | ||
| Q3 25 | 22.6% | -6.0% | ||
| Q2 25 | 23.8% | 33.5% | ||
| Q1 25 | 4.5% | 30.0% | ||
| Q4 24 | 37.8% | 21.6% | ||
| Q3 24 | 27.7% | 15.3% | ||
| Q2 24 | 27.5% | 16.9% | ||
| Q1 24 | 12.4% | 13.6% |
净利率ALKSBMRN
| Q4 25 | 12.8% | -5.3% | ||
| Q3 25 | 21.0% | -4.0% | ||
| Q2 25 | 22.3% | 29.1% | ||
| Q1 25 | 7.3% | 24.9% | ||
| Q4 24 | 34.1% | 16.7% | ||
| Q3 24 | 24.4% | 14.2% | ||
| Q2 24 | 22.9% | 15.1% | ||
| Q1 24 | 10.5% | 13.7% |
每股收益（稀释后）ALKSBMRN
| Q4 25 | $0.29 | $-0.22 | ||
| Q3 25 | $0.49 | $-0.16 | ||
| Q2 25 | $0.52 | $1.23 | ||
| Q1 25 | $0.13 | $0.95 | ||
| Q4 24 | $0.88 | $0.65 | ||
| Q3 24 | $0.55 | $0.55 | ||
| Q2 24 | $0.53 | $0.55 | ||
| Q1 24 | $0.21 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $6.1B |
| 总资产 | $2.5B | $7.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSBMRN
| Q4 25 | $388.6M | $1.3B | ||
| Q3 25 | $616.4M | $1.3B | ||
| Q2 25 | $521.2M | $1.2B | ||
| Q1 25 | $399.8M | $1.0B | ||
| Q4 24 | $291.1M | $942.8M | ||
| Q3 24 | $396.3M | $675.4M | ||
| Q2 24 | $535.1M | $972.1M | ||
| Q1 24 | $420.8M | $747.0M |
股东权益ALKSBMRN
| Q4 25 | $1.8B | $6.1B | ||
| Q3 25 | $1.7B | $6.1B | ||
| Q2 25 | $1.6B | $6.0B | ||
| Q1 25 | $1.5B | $5.8B | ||
| Q4 24 | $1.5B | $5.7B | ||
| Q3 24 | $1.3B | $5.4B | ||
| Q2 24 | $1.3B | $5.3B | ||
| Q1 24 | $1.3B | $5.1B |
总资产ALKSBMRN
| Q4 25 | $2.5B | $7.6B | ||
| Q3 25 | $2.3B | $7.6B | ||
| Q2 25 | $2.3B | $7.5B | ||
| Q1 25 | $2.1B | $7.1B | ||
| Q4 24 | $2.1B | $7.0B | ||
| Q3 24 | $2.2B | $6.9B | ||
| Q2 24 | $2.2B | $7.1B | ||
| Q1 24 | $2.1B | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $99.6M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $58.9M |
| 自由现金流率自由现金流/营收 | 44.2% | 6.7% |
| 资本支出强度资本支出/营收 | 0.0% | 4.7% |
| 现金转化率经营现金流/净利润 | 3.45× | — |
| 过去12个月自由现金流最近4个季度 | $480.3M | $725.0M |
8季度趋势，按日历期对齐
经营现金流ALKSBMRN
| Q4 25 | $170.1M | $99.6M | ||
| Q3 25 | $101.7M | $368.7M | ||
| Q2 25 | $150.2M | $185.3M | ||
| Q1 25 | $98.8M | $174.4M | ||
| Q4 24 | $190.4M | $185.6M | ||
| Q3 24 | $81.6M | $221.5M | ||
| Q2 24 | $146.0M | $118.8M | ||
| Q1 24 | $21.1M | $47.0M |
自由现金流ALKSBMRN
| Q4 25 | $170.0M | $58.9M | ||
| Q3 25 | $84.4M | $340.2M | ||
| Q2 25 | $137.2M | $168.2M | ||
| Q1 25 | $88.7M | $157.6M | ||
| Q4 24 | $180.6M | $166.1M | ||
| Q3 24 | $73.3M | $203.0M | ||
| Q2 24 | $138.9M | $97.4M | ||
| Q1 24 | $12.8M | $20.9M |
自由现金流率ALKSBMRN
| Q4 25 | 44.2% | 6.7% | ||
| Q3 25 | 21.4% | 43.8% | ||
| Q2 25 | 35.1% | 20.4% | ||
| Q1 25 | 28.9% | 21.2% | ||
| Q4 24 | 42.0% | 22.2% | ||
| Q3 24 | 19.4% | 27.2% | ||
| Q2 24 | 34.8% | 13.7% | ||
| Q1 24 | 3.6% | 3.2% |
资本支出强度ALKSBMRN
| Q4 25 | 0.0% | 4.7% | ||
| Q3 25 | 4.4% | 3.7% | ||
| Q2 25 | 3.3% | 2.1% | ||
| Q1 25 | 3.3% | 2.3% | ||
| Q4 24 | 2.3% | 2.6% | ||
| Q3 24 | 2.2% | 2.5% | ||
| Q2 24 | 1.8% | 3.0% | ||
| Q1 24 | 2.4% | 4.0% |
现金转化率ALKSBMRN
| Q4 25 | 3.45× | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | 0.77× | ||
| Q1 25 | 4.40× | 0.94× | ||
| Q4 24 | 1.30× | 1.49× | ||
| Q3 24 | 0.88× | 2.09× | ||
| Q2 24 | 1.60× | 1.11× | ||
| Q1 24 | 0.57× | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
